Lepodisiran

Last updated
Lepodisiran
Clinical data
Other namesLY3819469; LY-3819469
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Lepodisiran (LY3819469) is a small interfering RNA that was developed to reduce lipoprotein(a) in people at risk of cardiovascular disease. It was developed by Eli Lilly and Company. [1] [2]

As of March 31 of 2025, company trials in phase 2 of randomized, double-blind, placebo-controlled study resulted in significant reduction by the lepodisiran levels of genetically inherited cardiovascular risk factor such as heart attacks, strokes, thrombosis, nearly 94% from baseline. [3]

References

  1. Nissen, Steven E.; Linnebjerg, Helle; Shen, Xi; Wolski, Kathy; Ma, Xiaosu; Lim, Shufen; Michael, Laura F.; Ruotolo, Giacomo; Gribble, Grace; Navar, Ann Marie; Nicholls, Stephen J. (12 November 2023). "Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial". JAMA. 330 (21): 2075–2083. doi:10.1001/jama.2023.21835. ISSN   0098-7484. PMC   10641766 . PMID   37952254.
  2. Boyanovsky, Boris B. (July 2023). "Lipoprotein(a) Lowering Medications: Another Step Forward in Atherosclerosis Management". Journal of Cardiovascular Pharmacology. 82 (1): 32–36. doi: 10.1097/FJC.0000000000001438 . PMID   37192439.
  3. "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels". Eli Lilly and Company web page. March 30, 2025. Retrieved March 31, 2025.